Specification: |
With the CAS registry number 93384-43-1, Botulin A is also named as Botulinum Toxin Type A; Onabotulinumtoxina. It is lyophilized powder which is highly toxic and flammable. The product's categories are bacterianeurobiology; cell signaling and neuroscience; pharmacologicals; toxins; toxins and venoms. It will produce spicy smoke when buring. So the storage environment should be ventilate, low-temperature and dry. Keep Botulin A separate from raw materials of food. In addition, it is a protein produced by the bacterium Clostridium botulinum.
The Botulin A can be used as an effective and powerful medication. It is mainly used in iatrology and beauty. It is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. This material is also has many other uses, such as treatment of Pediatric incontinence, TMJ pain disorders and Wound healing. But the Botulin A also has many side effects. It can result in inappropriate facial expression such as drooping eyelid, double vision, uneven smile, or loss of the ability to close eyes In cosmetic us. Other adverse events from cosmetic use include headaches, dysphagia, flu-like syndromes, and allergic reactions.
When you are using this chemical, please be cautious about it as the following:
It is very toxic by inhalation, in contact with skin and if swallowed. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. After contact with skin, wash immediately with plenty of soap-suds. If you want to contact this product, you must wear suitable protective clothing and gloves. In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
The following are the toxicity data which has been tested.
Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
monkey |
LD |
intramuscular |
> 24units/kg (24units/kg) |
BEHAVIORAL: TREMOR
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
MUSCULOSKELETAL: OTHER CHANGES |
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 39, Pg. 655, 1997. |
mouse |
LD50 |
intraperitoneal |
160ng/kg (0.00016mg/kg) |
|
Toxicology and Applied Pharmacology. Vol. 28, Pg. 227, 1974. |
mouse |
LD50 |
subcutaneous |
4ng/kg (0.000004mg/kg) |
|
Toxicon. Vol. 24, Pg. 1065, 1986. |
mouse |
LD50 |
unreported |
30pg/kg (0.00000003mg/kg) |
|
Igaku No Ayumi. Progress in Medicine. Vol. 112, Pg. 861, 1980. |
rat |
LD50 |
intramuscular |
96units/kg (96units/kg) |
MUSCULOSKELETAL: OTHER CHANGES
SKIN AND APPENDAGES (SKIN): HAIR: OTHER |
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 39, Pg. 655, 1997. |
rat |
LD50 |
intravenous |
50units/kg (50units/kg) |
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
SKIN AND APPENDAGES (SKIN): HAIR: OTHER |
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 39, Pg. 655, 1997. |
rat |
LDLo |
subcutaneous |
1250mg/kg (1250mg/kg) |
PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE |
Journal of Physiology. Vol. 260, Pg. 177, 1976.
|
women |
TDLo |
intramuscular |
24iu/kg/2W-I (24iu/kg) |
PERIPHERAL NERVE AND SENSATION: STRUCTURAL CHANGE IN NERVE OR SHEATH
BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
BEHAVIORAL: MUSCLE WEAKNESS |
Journal of Neurology, Neurosurgery and Psychiatry. Vol. 56, Pg. 220, 1993. |
|